INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common type of childhood cancer. Glucocorticoids (GCs) are used for the treatment of ALL because of their ability to induce apoptosis in white blood cells, whereas in other cell types they have no effect or can increase survival. 1 GCs activate GC receptor (GR), which is a transcription factor that upon hormone binding translocates to the nucleus and regulates target gene expression by binding to GC response elements (GREs). 2 A better understanding of the mechanism of action of the GCs could identify more potent drugs to prevent resistance development and eliminate side effects, thus facilitating development of better treatment strategies.
GC-induced apoptosis 3 requires B-cell lymphoma 2 family members and most importantly pro-apoptotic Bim. Bim activates pro-apoptotic Bax through neutralization of pro-survival B-cell lymphoma 2 like members. [3] [4] [5] [6] [7] [8] The ability of GCs to selectively induce apoptosis in white blood cells is the main factor contributing to their therapeutic use. The current concept of GC-dependent apoptosis in leukemia entails the presence of a transcriptionally competent GR. 2, 9 In addition, GR auto-induction is specifically observed in some sensitive leukemia cells, whereas in most epithelial cells GR displays hormone-dependent downregulation of its own mRNA and protein. 3, 5, 6, 10, 11 The mechanistic base for this effect is not understood although c-Myb and Ets transcription factors were reported to selectively regulate the GR promoter in different leukemia cell types. 12 Both activating and repressive functions of the GR have been suggested to play a role in GR-mediated apoptosis. One of the major pathways important for GR function is the activator protein 1 (AP-1) transcription factor composed of the Jun/Fos family of homo and heterodimers. Several levels of control were reported for this crosstalk and both factors were found targeted for phosphorylation by the JNK pathway. [13] [14] [15] In addition, the interaction between GR, c-Jun and c-Fos is important in determining GR function, as the c-Jun-c-Jun-GR complex causes GC-dependent stimulation, whereas c-Jun-c-Fos-GR leads to GC-dependent repression on the mouse proliferin gene. 16 The type of hormone response elements on the target gene, cellular levels of AP-1 and cell types are other major determinants of regulatory factor activities. 17 Therefore, the outcome of transcriptional regulation through AP-1/GR crosstalk depends on the state of signaling pathways, the response elements and the composition of the protein complexes.
Several studies have successfully used microarray analysis to identify biomarkers or signaling pathways for cancer classification. 18, 19 For instance, Segal et al. 20 have presented an integrated analysis of microarrays in 22 different types of tumor and identified crucial molecular modules whose activity is coordinated in specific types of tumor. A few studies have focused on the analysis of kinetic profiles of gene expression in order to determine the relationship between temporal features of transcriptional control and gene function in relevant signal transduction pathways and cellular processes. 21, 22 A microarray study in GC-treated T-lymphoblastic cells has shown that B10% of the entire genome is regulated upon GC exposure. 23 We have been studying the effect of GCs on the dynamics of downstream targets and were able to construct a basic kinetic model of GR activation. 4 The present study of GC-induced apoptosis was carried out with the use of microarray time courses in the sensitive ALL cell line CEM-C7-14. In addition, to further understand the genome-wide regulation by GC in ALL, we conducted an integrated analysis of 82 new and previously published arrays 5, 24 derived from ALL patients and cell lines treated for various times with GCs. Together, these analyses indicated a potential functional link between the GR target Bim, AP-1 and the Ets gene family member Erg that has recently been identified as a crucial factor in leukemia development. [25] [26] [27] Our results suggest that Erg is expressed markedly in resistant, but not in sensitive, cells and that c-Jun is expressed differentially in sensitive vs resistant cell lines. c-Jun is recruited on the AP-1 site in the Bim promoter and Erg is recruited on the GR promoter in a transient fashion in sensitive cells. In contrast, such recruitments were not observed in resistant cells, thus linking c-Jun and Erg to GC resistance in ALL. Finally, we observed increased apoptosis in ALL cells treated with YK-4-279, a functional inhibitor of Erg, Fli1 and Etv1. 28, 29 This approach of studying gene expression kinetics provided a dynamic snapshot of most genes related to GR function and led to identification of a novel mechanism involved in GC resistance that can be a target of future therapies.
RESULTS

Genome-wide identification of GR target time series in CEM-C7-14 cell lines
On the basis of our previous study, 4 we hypothesized that by identifying different kinetic modes of GR dependent gene expression we could learn more about mechanistic details of the main determinants of cellular sensitivity to GCs. The CEM-C7-14 cell line sensitive to GC treatment (indicated as C7) was incubated for 0, 2 and 10 h with synthetic GC dexamethasone (Dex) to identify early and delayed GC response genes. 4 Microarray analysis showed altered expression of 2373 genes in total in GC-treated cells (Po0.05) (1863 genes after 2 h, 2083 after 10 h). Three hundred fifty-eight genes were found to have 41.5-fold change (Po0.05). The short time-series expression miner (STEM) software was used to distinguish between true and random patterns using algorithms specifically designed for clustering and comparing short time series of gene expression data. 30 Based on this method, the 358 genes mapped to 15 clusters (Supplementary Table 1) with three profiles containing apoptosis related genes (profiles 8, 12, 13) ( Figure 1 and Supplementary Table 1a and b). There were six profiles that showed gradual repression kinetics (profiles 0-4, 7), while three other profiles showed an oscillatory kinetics (profiles 5, 6, 9). The MYC (c-Myc) gene that is known to be repressed by GC 6 was identified in profile 7, and found to be downregulated at 2 and 10 h of treatment. Not many genes were repressed in C7 cells treated with Dex for 2 h and most of the downregulation occurred when treated with Dex for 10 h, suggesting that downregulation takes longer than activation.
There were six profiles with steady activation kinetics; these are profile 8 and 11-15. Profiles 13 and 8 have a more pronounced induction after 2 h, whereas profiles 11, 12 and 15 have more linear induction. GR targets such as GR itself, NR3C1, TSC22D3 (GC-induced leucine zipper) and NFKBIA (IkBa) displayed such linear kinetics. The distribution of apoptosis related genes in individual profiles was determined using gene ontology (GO) mapping via STEM and was indicated below each profile ( Figure 1 ). In five profiles (0, 5, 6, 9, 14, labeled ( À )) we were unable to perform GO mapping with STEM as there was no subset of five or more genes that belonged to a common GO category at level 3 or below of the GO hierarchy. We also did not identify any apoptotic genes by direct search against the GO. Interestingly, we only identified apoptosis related genes in the GC-activating profiles. 8, 12, 13 Around a third of the genes were clustered in profile 13, which included 112 genes with a delayed increase in gene expression upon GC treatment (Figure 1, profile 13 ). Several known GR targets (FKBP5, AKAP13 and ALOX5AP) were also included in this profile. Profile 13 has the highest percentage of apoptosis related genes (17.8%), including BCL2L11 (Bim) and others such as Jun (c-Jun), RUNX2 and DUSP6 (Figure 1 profile 13 ). Profile 13 also reflects a delayed pattern of GC-induced gene expression, which correlates with our previous data. 4 It has been reported that c-Jun is induced by GCs in ALL cells and that it targets Bim for activation in neuronal cells. 31, 32 These data indicated a potential functional link between the known and crucial GR target Bim and the AP-1 family member c-Jun.
We next examined these 358 genes for the presence of the consensus GRE using the Transcriptional Regulatory Element Database, 2000 base pairs up and downstream from the known or predicted transcription start site. We found that in total 33 genes contain the indicated consensus GRE 9, 33 (Supplementary Table 1 ). Out of these, 8 direct GR target genes were previously identified (green) and 25 are potentially novel targets (red). All 33 genes were upregulated by Dex in the GC kinetic profiles 8 and 12-15.
Microarray analysis in GC-treated sensitive and resistant ALL cell lines and patients To identify potential clinically relevant biomarkers of ALL sensitivity to GCs, we analyzed our microarray data from C7 cells together with data from the Gene Expression Omnibus (Supplementary Figures  1 and 2) . 5, 24 The data include GC sensitive, sensitivity-restored and resistant ALL treated with GCs at various times from 0 up to 24 h (with times between 6-10 h categorized as a single time point) (Supplementary Figure 2) . GC sensitivity was restored in resistant CEM-C1 ratGR and CEM-C7R1 dim-high cells by overexpression of rat GR and human GR dim mutant, respectively; the details can be found in supplementary files in Schmidt et al. 24 In total, 63 arrays from two microarray studies (Affymetrix HGU133 plus 2.0, Affymetrix, Santa Clara, CA, USA) were combined with our own data obtained from GC-treated C7 cells (5 arrays). The data were pre-processed and normalized based on cell subtypes by robust multi-array average using Bioconductor. 34 The log (base 2) of the expression value of genes in each array was calculated via robust multi-array average, and the list of significantly altered genes was calculated by significance analysis of microarray by grouping ALL data samples according to phenotypes (Table 1a and Supplementary Table 2) .
Hierarchical clustering was performed to provide a view of the distances between gene expression profiles in different types of ALL. Sensitivity-restored ALL were not included in this analysis as the hierarchical clustering showed that the overall genomic profile of sensitivity-restored ALL was more similar to resistant than sensitive cells (Supplementary Figure 1) . To take the sequential nature of time-series data into account, we performed a comparative analysis of two sets of data using STEM (Supplementary Figure 2 ). We pre-set the number of kinetic profiles 35 in STEM, so as to obtain genes either being linearly up-or downregulated by GC to achieve better grouping of gene expression results (Table 1a and Supplementary Table 2 ).
An additional 14 arrays were obtained from 10 children with Philadelphia positive (Ph þ ) ALL treated uniformly. They were categorized as good risk if the marrow had o25% blasts after 8 days of therapy without imatinib and poor risk if the blast count was 425%. During this time they received 8 days of Dex and one dose each of anthracycline, vincristine and L-Asparaginase. 36 The data were analyzed similarly and the Limma t-test was used to determine significant induction/repression (Table 1b and  Supplementary Table 3 ).
When the data obtained from the 68 arrays (63 plus 5 arrays as described above) was compared with the 14 arrays obtained from the Ph þ patients, only NFE2, BCL2A1, NCF2 (Ncf2), LGALS3, ERG (Erg) and GBP4 showed a consistent and significant differential regulation (Table 1, Supplementary Tables 2 and 3 ). c-Jun was not identified as one of the significantly regulated genes in this case (Table 1 ). In particular, only Ncf2 and Erg had a steady regulatory dynamics, with Erg showing a stronger differential regulation. Ncf2 was upregulated in both sensitive ALL and patients (1.42 log2-fold) and in Ph þ ALL (1.76 log2-fold). Erg was also identified as a significantly differentially regulated gene between sensitive and resistant cell lines (Po0.05, fold change 42), as well as between Ph þ ALL patients with good or poor risk. Erg showed a consistent significant repression in both sensitive cell lines ( À 1.29 log2-fold) and in Ph þ ALL ( À 2.39 log2-fold) patients with good risk. Such repression was not found in resistant cell lines or in Ph þ ALL patients with bad risk (Supplementary Table 2b, Supplementary Table 3b) . Given the consistency, the magnitude of Erg repression and its role in leukemia, 24 Erg was chosen for further study.
Validation of microarray analysis identifies potential role of the GR/AP-1/Erg in control of the GR and Bim expression Our microarray analysis pointed towards c-Jun ( Figure 1 ) and Erg (Table 1) as potential biomarkers of GC response. Direct interactions between Erg, the Jun/Fos complex (also called the AP-1 complex) and various other Ets proteins were shown previously. 37 GR auto-regulation in ALL is controlled by Ets family members such as PU.1, c-Ets-1 and c-Ets-2, which downregulate GR auto-induction via a composite hGR1A promoter element in IM-9 B-cells. 12 Given the well documented crosstalk between AP-1 and GR pathways 17 and the importance of Erg in leukemia development, 25 we analyzed how these pathways control GR and Bim function since these two genes are major contributors to the GC response. In order to test the predictions of the microarray analysis we determined the protein levels of candidate genes in C7 and GC-resistant CEM-C1-15 (indicated as C1) cells treated with GCs ( Figure ( Figure 2 and Supplementary Figures 3, 4) . In C1 cells treated for 24 h with Dex, an upregulation of Erg protein level was found (Supplementary Figure 4) . c-Fos expression was not detected with longer Dex treatment in CEM cells, but was clearly identified in A549 lung cancer cells using the same antibody (Supplementary Figure 4) . To investigate whether the identified changes of protein levels were due to effects on gene expression we determined mRNA levels using qRT-PCR (Figures 3a and b) . The results confirmed that Bim, c-Jun and GR were differentially expressed in C7 cells (Figure 3a) . mRNA expression levels of Bim and c-Jun were significantly upregulated by 44-fold 10 h after Dex treatment in GC-sensitive C7 cells. Similar analysis in Dex-treated GC-resistant C1 cells indicated an increase in Erg mRNA that was not significant after 10 h of treatment (according to Tukey's test) and a 4-fold significant upregulation in Erg after 24 h treatment, which is much higher than in C7 cells (Figure 3 and Supplementary Figure 4a) . Overall, the validation of microarray data pointed to c-Jun and Erg as potentially important biomarkers of GC sensitivity in ALL.
c-Jun and Erg occupy Bim and GR promoters, respectively, in C7 cells We have identified a potential AP-1 response element in the Bim promoter (Supplementary Table 4a) . 38 Chromatin immunoprecipitation assays were performed to determine whether Dex increased the c-Jun, c-Fos and Erg occupancy on the Bim promoter at AP-1 site. Dex treatment induced c-Jun binding to the Bim gene after 10 h treatment (Figure 4a ), but did not induce c-Fos binding to Bim. As Erg has been found to interact with the AP-1 transcription factor, 37 our next aim was to analyze if Erg occupies the AP-1 site on Bim. The result indicated that Erg was not recruited in a hormone-dependent manner on the AP-1 binding site in Bim in sensitive cells (Figure 4b) .
It was previously shown that Ets family members have a role in GR auto-regulation. 12 The Ets family member consensus sequence GGA(A/T) was found in footprint 12 (FP12), which is adjacent to a half GRE (FP11), and both sites are important for determining hGR1A promoter responsiveness. Here, we identified an Erg consensus sequence (C/A) GGAA(G/A) 39 at the same site at footprint 12 (261 bp downstream of hGR1A) (Supplementary Table 4B ). Erg was efficiently and transiently recruited on the GR1A promoter in sensitive cells (Figure 4c) . However, AP-1 and Erg were not efficiently recruited on Bim and GR promoters in resistant cells ( Figure 5 ). Overall, we identified hormone-dependent recruitment of c-Jun on the Bim promoter AP-1 site and a transient recruitment of Erg on the hGR1A only in sensitive but not resistant cells.
Erg inhibition increases ALL cell death Our results indicated that Erg and c-Jun are potentially important molecules in regulating GR gene expression and GC sensitivity. As the JNK pathway is involved in regulating activity of both GR and AP-1/Erg proteins, 40,41 the JNK inhibitor SP600125 was used to investigate its effects on cell fate. In addition, the Y-K-4279 compound that inhibits Erg subfamily of proteins 29 was used individually or in combination with Dex to analyze its effects on ALL cellular fate ( Figure 6 ). Dex treatment increased the percentage of apoptotic cells in C7 but not in C1 cells, whereas treatment with the Erg inhibitor caused an increase in apoptotic cells in C1 but not C7 cells. Combination of Dex and Y-K-4279 treatment increased apoptotic cell death in both cell lines. Treatment of C7 and C1 lines with JNK inhibitor resulted in a minor but insignificant increase in apoptosis, whereas it significantly increased apoptosis when combined with Dex in C7 cells. These results indicated that inhibiting Erg and JNK pathways in hormone treated cells displays selective effects on apoptosis of sensitive and resistant cells.
DISCUSSION
The molecular basis of GC-induced apoptosis and resistance is not fully understood. Our microarray analysis identified the association between AP-1, c-Jun and Erg in relation to GR function in leukemia. As the pro-apoptotic Bim gene is a crucial node in GRmediated apoptosis and a known c-Jun target in neuronal cells, 32 we analyzed the interplay of these factors in the control of Bim function. This was also applied to the control of GR autoregulation. Fifteen kinetic profiles of GR regulated genes were found in GCtreated C7 cells for 0, 2 and 10 h. Two hundred sixty-eight out of 358 genes were activated by the GR, suggesting that activation is more prevalent in leukemia. The analysis also identified sets of early and delayed responsive genes to GCs (Figure 1 ). These findings highlight the importance of studying the kinetics of gene expression and suggest that GR utilizes differential regulatory mechanisms to control target gene transcription. GRE containing 9 and apoptotic genes were exclusively found in GC-activated clusters (Figure 1 ), suggesting that GCs activate rather than repress most of the apoptotic genes in C7 cells.
We have identified c-Jun as a crucial target in GR and Bim regulation (Figures 2 and 3) . 31, 32 This result was supported by the observation that c-Jun is induced by GCs in leukemia and targets Bim in neuronal cells. 30, 31 We determined that c-Jun is recruited to the Bim promoter in C7 cells only (Figures 4, 5) . A recent study indicated that AP-1 facilitates cell-specific GR recruitment by maintaining chromatin accessibility. The complex crosstalk between GR and AP-1 transcription factors involves both mutual activation and inhibition, 17 but our data indicate that the major regulatory effect occurs through GR dependent c-Jun upregulation, which then selectively activates Bim gene expression in a cell-specific manner (Figures 2-5 ). On the other hand, there was virtually none or very low expression of the AP-1 subunit c-Fos in CEM cells and no relevant recruitment was observed on the Bim promoter (Figures 2-5 ). It is thought that the c-Jun-c-Fos heterodimer leads to GC-dependent repression and that the c-Jun-c-Jun homodimer causes GC-dependent stimulation in some target genes. 42 We did not observe c-Fos level increase/ recruitment on Bim promoter in the resistant C1 cells. It should be noted that the arrangement of GR and AP-1 binding sites is another major determinant of the regulatory factor's activities. 43 For instance, when two sites are not closely juxtaposed, GR and AP-1 act synergistically regardless of the composition of AP-1, however, if the two sites are close to each other [14] [15] [16] [17] [18] then they act as a composite GRE where activation/inhibition occurs in a contextdependent fashion. 44, 45 Furthermore, the interaction of AP1 and GR with other transcription factors such as the GC-induced leucine zipper can influence the GC response. 46 Taken together, the interaction between GR, c-Jun and c-Fos is regulated at multiple levels including AP-1 composition, DNA-binding specificity and interaction with other transcription factors. Precise details of this crosstalk and the role of c-Fos in GC response require additional research.
The activity of c-Jun is regulated by the JNK pathway. In T-ALL, the c-Jun/JNK pathway has been implicated in both pro-and antiapoptotic effects. 47, 48 However, c-Jun induction was observed in C7 cells and in T-ALL patients after GC treatment and a higher basal expression of c-Jun was detected in sensitive than in the resistant T-ALL. 31, 49 A recent study indicated that c-Jun may potentially be activated through p38 MAPK as well, thereby regulating Bim and inducing apoptosis. 50, 51 JNK dependent c-Jun phosphorylation at Ser63 and Ser73 has been linked to c-Jun activation. 52 The change in Ser63 phosphorylation in c-Jun has been shown to correlate with protection of BimEL from degradation. 48 c-Jun phosphorylation at Ser63 has also been implicated in nitric oxide-induced apoptosis in neural tumors. 53 In addition, JNK targets GR for phosphorylation and this is proposed to inhibit GR activity at certain promoters. Therefore, JNK could have a dual role in apoptosis through stimulation of c-Jun and Bim phosphorylation and inhibition of GR activity. Further investigations of the role of c-Jun phosphorylation in GCinduced apoptosis of ALL cells are thus required.
Microarray analysis of patients' and cell line data, generated by this and previous studies 5, 24 (Table 1 and Supplementary Table 2 ) identified Erg as one of the significant differentially regulated genes between sensitive and resistant ALL. This is consistent with results found in children with Ph þ ALL where Erg repression was found in patients with good risk (Supplementary Tables 2b and  3b ). This repression was, however, not identified in sensitive C7 cells, though there was a marked differential Erg expression compared with the resistant CEM cells (Figure 2 and Supplementary Figure 4a) . As the microarray analysis was based on the phenotypes only, various subtypes or other factors may introduce noise in the analysis, which also explains why Jun was not identified.
Erg belongs to an Ets transcription factor family deregulated in prostate cancer and fused to Ewing's sarcoma family members. 54 The important role of Erg in cell proliferation in leukemia has been found in many recent studies, [25] [26] [27] where high Erg expression is an adverse prognostic factor in adult T-ALL patients. 55, 56 Our results suggest that Erg is expressed markedly in resistant cells only (Figures 2 and 3) and that prolonged Dex treatment for 24 h differentially induces Erg protein and mRNA in resistant cells (Figures 2 and 3; Supplementary Figure 4a) .
Crosstalk between Ets family and GR has been described previously. 12 In GC-responsive T cells, the c-Myb transcription factor increases GR auto-regulation, whereas Ets family members such as PU.1 have repressive effect in GC-resistant B lymphocytes. However, Ets1-2 factors, which suppress Dex induction of the hGR1A promoter, also cause a large increase in basal promoter activity. In addition, the authors proposed that other Ets factors may be involved in earlier hGR1A transcriptional control in T cells. 12 Our data identified Erg as a potential candidate for such a function, either through basal regulation or as a pioneer factor. However, we could not detect any Erg occupancy that is hormone dependent on the hGR1A promoter in C1 cells despite high Erg protein levels in these cells (Figures 2 and 5b , and Supplementary Figure 4) . It is possible that unlike PU.1, Erg does not has a role in repressing the GR promoter in C1 cells or that it binds somewhere else on the promoter. It seems that Erg and c-Jun have opposite expression patterns ( Figures 2 and 3 and Supplementary Figure 4) . Crosstalk of AP-1 and Ets transcription factors has been described, 57 showing that they regulate gene transcription in a sequence, position, binding affinity and stimulus-dependent manner. A genome-wide analysis of Erg occupancy identified an overlap with AP-1 at prototypical Ras responsive elements, but Erg activates transcription from these elements in a Ras/MAPK-independent manner. 45 Thus, it is possible that overexpression of Erg in C1 cells reflects disturbed feedback loops between AP-1, Erg, MAPK pathways and GR. The importance of this balance is reflected in other studies where AP-1 was found to facilitate chromatin accessibility and GR binding. 44 An anti-apoptotic effect of Erg has been identified in umbilical vein endothelial cells 58 corroborating our results where the inhibition of Erg subfamily members increases apoptosis ( Figure 6 ). Such effect is GC dependent in sensitive and GC independent in resistant cells. The anti-apoptotic role of Erg may be due to various factors. First, it has been found that siRNA specific for Erg directly downregulates c-Myc in prostate epithelial cells. 59 The repression of c-Myc is known to be important in initiating apoptosis in GC-treated CEM cells, 60 which indicates a potential role of Erg in inhibiting apoptosis via regulation of c-Myc. However, such regulatory mechanism remains questionable as Lö ffler et al. 61 demonstrated that the repression of c-Myc is not critical for cell death. In leukemia, an association between Erg and Notch1 mutations was identified. As Notch1 is important in conferring GC resistance, this suggests another possible mechanism through which Erg can control GC-dependent apoptosis. 25 Other roles such as fusion with Ewing's sarcoma family protein members 62 and potential regulation of antiapoptotic BclX L 63 may also be considered. Although our study highlights the anti-apoptotic effect of Erg (as shown in Figure 6 ), we observed a transient Erg recruitment on the GR promoter in C7 cells. As the repressive role of Ets proteins in GR regulation has been proposed, 12 the effect of Erg transient recruitment on GR promoter in GC-induced apoptosis of C7 cells remains to be determined.
To summarize, we propose that GC sensitivity in ALL is controlled through a series of feedback loops operating in differential temporal patterns that will at least in part determine cellular levels of GR, AP-1, Erg and Bim, ultimately contributing to cell fate. In GC-treated C7 cells, GR becomes activated and alters Bim and GR transcription, potentially through AP-1 and Erg recruitment, respectively. Such recruitments were not seen in C1 cells. Other factors such as MAPK signaling and c-Myb may have a role in regulating GR, AP-1 and Bim, possibly through binding to the GR promoter. These relations could be used for improvement of current therapies and provide the basis for potential differential treatment of leukemia.
MATERIALS AND METHODS
Cell culture and treatments GC-responsive leukemia (C7) and GC-resistant leukemia (C1) cell lines 64 were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin (Cambrex, East Rutherford, NJ, USA) and were seeded into 60 mm plates for RNA extraction. Before the hormone treatment the media was changed to RPMI-1640 supplemented with 10% charcoal stripped fetal bovine serum (HyClone, Logan, UT, USA). Cells were treated with 1 mM Dex (Sigma, St Louis, MO, USA) at indicated time points (for 0, 2 and 10 h).
RNA extraction
Cells were harvested and the total RNA was extracted using the RNeasy plus mini kit and QIAshredder (Qiagen, Hilden, Germany), following manufacturer's guidelines and RNA was quantified using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). RNA quality was determined by means of an RNA 6000 NanoAssay on an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA).
Microarray and bioinformatics analysis
For each hybridization, 100 ng of total RNA was used in the Affymetrix GeneChip Two-Cycle Target Labeling kit and in the Ambion MEGAscript T7 kit (Ambion, Paisley, UK) before hybridizing to the GeneChip human genome U133 Plus 2.0 array (Affymetrix) according to manufacturer's instructions. Technical quality control was performed with the dChip software. 65 Background correction, normalization and gene expression analysis were performed using robust multi-array average analysis in the Bioconductor software package. 66 Differential expression analysis in C7 was performed using routine analytical methods. 67 GO mapping, statistical analysis, including significance analysis of microarrays and Limma t-test, and cluster analysis were performed with the use of the TIGR (The Institute for Genome Research) MultiExperiment Viewer (MeV) program 68 and STEM version 1.3.7 (Carnegie Mellon University). 69 Potential GRE sites were identified using the Transcriptional regulatory element database 32 or via text mining tools-The Champion ChiP Transcription Factor Search Portal (CCTSF) from Qiagen SABiosciences's database.
Quantitative real-time polymerase chain reaction Quantitative real-time PCR analysis was performed using the Bio-Rad Chromo4 system (Opticon monitor 3 software version) (Bio-Rad, Hercules, CA, USA), SensiMix SYBR No-ROX Kit (Bioline, London, UK), and indicated primer pairs. Relative quantification was performed using standard curves generated for each gene-specific primer pair. Analysis was carried out using the Opticon monitor 3 software as described previously. 70 The primers used in this study were: Rpl19: F: Immunoblotting analysis Immunoblotting procedures were as described previously. 4 In brief, cells were lysed in HSL buffer (45 mM HEPES pH 7.5, 400 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 10% glycerol, 0.5% NP-40, 1 mM DTT, 1 mM PMSF, protease inhibitor cocktail including 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 20 mM b-glycerophosphate, 5 mM sodium pyrophosphate and 2 mM sodium orthovanadate). Equal amounts of protein were loaded and resolved by SDS-PAGE, transferred to Immobilon-P membrane (Millipore, Billerica, MA, USA) using western blot and probed with indicated antibodies. The following antibodies were used: GR (H-300), c-Jun (H79), c-Fos (H-125), Erg (D-3) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); Actin and Bim antibodies were purchased from Abcam (Cambridge, UK); p-Jun (Ser63) was from Cell Signaling (Beverly, MA, USA). Blots were developed with the enhanced chemiluminescence substrate according to manufacturer's instructions (Pierce Chemical, Pierce, IL, USA). The quantification of blots was performed by using the ImageJ software. The relative intensity of c-Jun phosphoisoforms to the total c-Jun was determined by the ratio against the total c-Jun vs actin as reported in Lynch et al. 71 
Chromatin immunoprecipitation analysis
The procedure for chromatin immunoprecipitation was adapted from Schmidt et al. 72 Briefly, 5 Â 10 7 cells from culture treated with 1 mM Dex at indicated time points were cross-linked by adding formaldehyde to achieve a final concentration of 1%. Cross-linked chromatin was sonicated to yield a size range from 200-1200 bp (Bioruptor, Diagenode, Denville, NJ, USA) and the debris was removed by centrifugation. The chromatin solution was pre-cleared with protein G beads (Invitrogen, Paisley, UK) and incubated with the indicated antibodies overnight at 4 1C. The used antibodies were non-specific IgG (GE healthcare, Bucks, UK), c-Jun (H79), Erg and AP-1 in acute lymphoblastic leukemia DW-C Chen et al Fluorescence-activated cell sorting (FACS) analysis and annexin V staining CCRF-CEM cells were plated in six-well plates in RPMI-1640 supplemented with 10% DCC-FBS and incubated overnight. In all, 1 mM Dex, 10 mM YK-4-279 or 10 mM JNK inhibitor (SP600125) were added to the medium and cells were incubated for 48 h. Apoptosis was assessed using an Annexin V kit (AbD Serotec, Oxford, UK) according to the instructions of the manufacturer. Briefly, after washing in PBS, cells were resuspended in annexin buffer and incubated with annexin V-FITC for 10 min followed by incubation with propidium iodide. All data were acquired on a CyAN ADP flow cytometer and analyzed with the use of Summit software (DakoCytomation, Dako, Glostrup, Denmark).
Description of ALL types used in the analysis
The 63 selected arrays described in 5, 24 (Gene Expression Omnibus accession numbers: GSE2677, GSE2842 -Supplementary Table 5) ABBREVIATIONS GC, glucocorticoid; GR, glucocorticoid receptor; GRE, glucocorticoid response element; Bcl-2, B-cell lymphoma 2; Dex, dexamethasone; Erg, Ets related gene; p-Jun, phospho-c-Jun; AP-1, activator protein 1.
